鲜为人知的是，这已是康桥资本CEO、董事总经理傅唯过去三年参与创立并成

Little-known is that this is the second pharmaceutical company that Fu Wei, CEO and managing director of Cambridge Capital, has participated in the establishment and successful listing in the past three years. In January this year, Tianjing Bio was listed on NASDAQ. Participating in the establishment of Tianjing, Cambridge Capital has invested in three consecutive rounds, and the stock price has risen by 180% compared with the issue price, which has become a classic case in the history of global medical investment in recent years. <br><br>And these are just the beginning. Since its establishment in 2014, Cambridge Capital has established a total of 10 companies, and has created a series of high-return cases with the "incubation" investment strategy. Taking Genting Xinyao as an example, Cambridge Capital has invested a total of US$200 million. Based on today's market value of HK$21 billion, this investment has created a return of 10 billion for Cambridge. <br><br>A 38-year-old investor went off to start a business: in just three years, it achieved a market value of 20 billion. This is not a history of a scientist who worked hard and sharpened his sword for ten years, but a story of a young investor who found a new way and broke out of the jungle.

It is little known that this is the second pharmaceutical company that Fu Wei, CEO and managing director of Kangqiao capital, has participated in the establishment and successful listing in the past three years - Tianjing bio landed on NASDAQ in January this year. Since 2016, Kangqiao capital has participated in the establishment of Tianjing. Kangqiao capital has invested in three consecutive rounds, and its share price has risen 180% compared with the issue price, becoming a classic case in the history of global medical investment in recent years.<br>And these are just the beginning. Since its establishment in 2014, Kangqiao capital has established 10 companies in total and created one case of ultra-high return with the "incubation" investment strategy. Taking Yunding Xinyao as an example, Kangqiao capital has injected US $200 million. Based on today's market value of HK $21 billion, this investment has created a return of 10 billion for Kangqiao.<br>A 38 year old investor ended up starting a business: in just three years, he achieved a market value of 20 billion. This is not an entrepreneurial history of painstaking efforts by a scientist and grinding a sword for ten years, but a story of a young investor who found another way and fought out of the jungle.

Little known is that this is the second pharmaceutical company founded and successfully listed by Fu Wei, CEO and managing director of Kangqiao Capital in the past three years. In January this year, Tianjing Bio landed on Nasdaq, and since 2016, it has participated in the founding of Tianjing. Kangqiao Capital has invested for three consecutive rounds, and its share price has increased by 180% compared with the issue price, which has become a classic case in the history of global medical investment in recent years. And these are just the beginning. Since its establishment in 2014, Kangqiao Capital has established 10 companies in total, and with the "incubating" investment strategy, it has created a case of ultra-high return. Take Genting Xinyao as an example, Kangqiao Capital has invested a total of US$ 200 million. Based on today's market value of HK$ 21 billion, this investment has created a return of 10 billion for Kangqiao. A 38-year-old investor started his business: in just three years, he achieved a market value of 20 billion yuan. This is not the entrepreneurial history of a scientist who worked hard for ten years, but the story of a young investor who found a new way out of the jungle.